- Home
- INTS vs APM Comparison
INTS vs APM Comparison
Compare INTS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- APM
- Stock Information
- Founded
- INTS 2012
- APM 2010
- Country
- INTS United States
- APM United Kingdom
- Employees
- INTS N/A
- APM N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- APM Health Care
- Exchange
- INTS Nasdaq
- APM Nasdaq
- Market Cap
- INTS 8.4M
- APM 6.9M
- IPO Year
- INTS 2023
- APM 2018
- Fundamental
- Price
- INTS $0.30
- APM $2.64
- Analyst Decision
- INTS Strong Buy
- APM
- Analyst Count
- INTS 4
- APM 0
- Target Price
- INTS $4.50
- APM N/A
- AVG Volume (30 Days)
- INTS 5.8M
- APM 20.0M
- Earning Date
- INTS 08-07-2025
- APM 04-30-2025
- Dividend Yield
- INTS N/A
- APM N/A
- EPS Growth
- INTS N/A
- APM N/A
- EPS
- INTS N/A
- APM N/A
- Revenue
- INTS N/A
- APM N/A
- Revenue This Year
- INTS N/A
- APM N/A
- Revenue Next Year
- INTS N/A
- APM N/A
- P/E Ratio
- INTS N/A
- APM N/A
- Revenue Growth
- INTS N/A
- APM N/A
- 52 Week Low
- INTS $0.19
- APM $0.46
- 52 Week High
- INTS $4.35
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- INTS 49.95
- APM 59.96
- Support Level
- INTS $0.28
- APM $1.26
- Resistance Level
- INTS $0.32
- APM $4.47
- Average True Range (ATR)
- INTS 0.03
- APM 0.26
- MACD
- INTS 0.01
- APM 0.17
- Stochastic Oscillator
- INTS 78.80
- APM 43.87
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.